Portfolio company
Artios
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
Artios develops DNA damage response small molecule therapeutics for patients with solid tumours and various cancer types.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Artios Pharma Limited
The company develops DNA damage response inhibitors for patients with solid tumours to overcome cancer cell survival and treatment resistance.
Aprea Therapeutics
This company develops targeted cancer therapies for patients with biomarker-defined tumours and DNA damage response pathway defects.
ARase Therapeutics
This company develops small molecule drugs targeting ADP-ribose hydrolases for patients with various forms of cancer.
iOnctura
The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.
Aktis Oncology
This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.
FoRx Therapeutics
The company develops oral small molecule drugs targeting DNA replication stress for patients with treatment-resistant cancers.
Actithera Group
This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.
NeoPhore
This company develops small-molecule immuno-oncology medicines that inhibit DNA mismatch repair to stimulate immune responses against cancer for patients with solid tumours.